Lorundrostat is an oral aldosterone synthase inhibitor targeting the treatment of hypertension, obstructive sleep apnoea, and ...

Mineralys Therapeutics (MLYS) announced detailed results from the pivotal Phase 3 Launch-HTN trial in over 1,000 participants ...

Mineralys expects to announce top-line data from the Explore-CKD trial later in the current quarter. The Chief Executive Officer confirmed the company's intention to submit an NDA for lorundrostat ...

The last time I wrote about Mineralys Therapeutics (NASDAQ:MLYS) it was with respect to a Seeking Alpha article entitled "Mineralys: 2nd Half 2024 Hypertension Data Readout". In this article ...

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension ...

Mineralys Therapeutics is working on a treatment for patients with uncontrolled hypertension. New York veterinary operator opens Main Line clinic © 2025 American ...

Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.

M.D., Chief Medical Officer for Mineralys. "We believe this trial confirms the link between obesity, excess aldosterone production and hypertension. Based on the beneficial response observed in ...

Abnormal aldosterone production is considered a key driver in uncontrolled and resistant hypertension,” stated Jon Congleton, Chief Executive Officer of Mineralys. “Lorundrostat has already ...

March 10 (Reuters) - Mineralys Therapeutics (MLYS.O), opens new tab said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and ...

Mineralys Therapeutics Inc., the third company this week to sell more shares than it had planned in its IPO, rose 15% in New York trading Friday after raising $192 million in its initial public ...